317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors

• Leisha Emens,
• Naomi Hunder,
• Samuel Klempner,
• Erika Hamilton,
• Muralidhar Beeram,
• Valerie Odegard,
• Sue Hamke

Affiliations

Leisha Emens

Aff501 grid.21107.350000000121719311Johns Hopkins University School of Medicine Baltimore MD USA

Naomi Hunder

Aff12 grid.419971.3Formerly of ZymoGenetics (Bristol-Myers Squibb) Seattle WA USA

Samuel Klempner

1Massachusetts General Hospital, Boston, MA, USA

Erika Hamilton

3Sarah Cannon Research Institute, Nashville, TN, USA

Muralidhar Beeram

2The Start Center for Cancer Care, San Antonio, TX, USA

Valerie Odegard

5Silverback Therapeutics, Inc., Seattle, WA, USA

Sue Hamke

5Silverback Therapeutics, Inc., Seattle, WA, USA